Weight Loss

After participating in a 12-week lifestyle intervention followed by 72 weeks of tirzepatide, adults with obesity lost a mean of 24.3% of their body weight, researchers reported.

VANCOUVER, British Columbia — Tirzepatide 15 mg was associated with the highest degree of weight loss compared with other glucagon-like peptide-1 agonists and placebo, according to a presenter at the ACG Annual Scientific Meeting.

DALLAS — Adults with obesity and a genetic mutation that causes deficiency in the melanocortin-4 receptor (MC4R) pathway lost a similar amount of weight with tirzepatide as adults without a genetic mutation, according to a speaker.

BOSTON — In this Healio video exclusive, Donna H. Ryan, MD, and Christopher Still, DO, FACP, discuss the optimal treatment strategy for patients who require weight loss beyond diet and lifestyle changes.

Women with less access to mammogram screening and women with obesity had higher breast cancer mortality rates, according to a study published in JAMA Network Open.

DALLAS — New data presented at ObesityWeek demonstrate an encouraging early profile of an investigational dual GLP-1/GIP receptor agonist in healthy adults, according to a speaker at ObesityWeek.

DALLAS — Older adults who received anti-obesity medications lost a similar amount of weight at 3 to 5 years as younger adults, with no increased side effects, according to research presented at ObesityWeek.

DALLAS — Social vulnerability appears to attenuate weight loss at 10 years among adolescents who underwent metabolic and bariatric surgery, researchers reported at ObesityWeek.

DALLAS — Weight loss with the triple-hormone agonist retatrutide varies by sex, age and baseline BMI, according to a speaker.

Older women who had 5% or more unintentional weight loss had lower life expectancy compared with women with stable weight, according to data from the Women’s Health Initiative published in The Journals of Gerontology.